Anixa Biosciences Reports Improved Q3 Net Loss of $2.52M, $13.7M Cash Extends Runway
ANIX is trading near its 52-week low of $2.35 (0.4% above the low).
Summary
Anixa Biosciences reported a Q3 2026 net loss of $2.52 million, an improvement from $2.79 million in the year-ago quarter, with EPS improving to $(0.07). The company ended the quarter with $13.686 million in cash and short-term investments, down about $1.5 million from October 2025. This cash position, combined with a recent $2.87 million raised through an at-the-market offering, is expected to fund operations for more than 12 months. This financial update follows recent positive clinical progress for its breast cancer vaccine and CAR-T programs, as noted in the 10-Q filed earlier today. For a pre-revenue biotech, extending the cash runway is a critical indicator of operational stability.
At the time of this announcement, ANIX was trading at $2.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.8M. The 52-week trading range was $2.35 to $5.46. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.